Analysis of Factors Affecting the OEM Production Cycle of Health Products and Reasons for Delivery Delay

In 2026, as the trillion dollar health industry accelerates its expansion,OEM manufacturing of health productsThe mode has become the core path for brand owners to quickly layout the market, but production cycle control and delivery stability have always been the key pain points that plague brand owners. Especially with the implementation of the "Measures for the Supervision and Administration of Food Commissioned Production (Draft for Comments)" by the end of 2025 and the imminent implementation of General Administration of Customs Order No. 280 in 2026, compliance supervision is becoming increasingly strict, further extending the production cycle of some products and significantly increasing the risk of delivery delays. This article combines industry regulations and frontline OEM practices to analyze the core influencing factors of the OEM production cycle for health products, dissect the high-frequency reasons for delivery delays, and provide reference for brand owners to avoid risks and promote OEM projects.

1、 Core influencing factors of OEM production cycle for health products (with industry benchmark cycle attached)

The OEM production cycle of health products is not a fixed value and is significantly affected by multiple factors such as product characteristics, supply chain, and compliance requirements. Industry data shows that the standard production cycle for ordinary food health products (SC qualification) is 30-60 days, while health foods with a "blue hat" can take up to 6-12 months due to pre filing requirements; The mature formula products of top OEM companies can compress the cycle to 15-25 days, and emergency orders can even be shipped within 7 days, with the gap mainly due to the following six core factors.

（1） Product and formula complexity: determines the production base week

The characteristics of the product itself are the primary prerequisite that affects the cycle, and the differences in formula, dosage form, and specifications directly determine the length of time required for sampling and production.

In terms of formula, mature standard formulas do not require repeated debugging, and sampling only takes 3-7 days, which can quickly enter the mass production stage; New formulas and complex compound formulas require multiple formula adjustments and stability tests to ensure that the effective ingredient content meets the standards and the taste and form meet the requirements, which will add an additional 10-20 day cycle. Especially under the new regulations, formulas need to meet stricter quality standards, and the testing cycle for some complex formulas will be further extended.

The impact of dosage form differences on the cycle is more significant: conventional dosage forms such as tablets, powders, and granules have mature processes, simple production processes, and single batch production only takes 5-10 days; The production process of dosage forms such as soft capsules, oral liquids, and effervescent tablets is complex, requiring additional steps such as equipment debugging and sealing testing, which can increase the cycle by more than 30%; Pastry and extraction products require long-term boiling, concentration, and precipitation, with a single cycle saving time of 15-20 days.

In addition, customized requirements will also prolong the cycle. If the brand requires irregular bottles, special packaging materials, or exclusive anti-counterfeiting designs, additional mold opening and sample confirmation are required, usually adding 5-10 days; The personalized label design of some brands may indirectly prolong the preparation time if it involves repeated compliance audits.

（2） Supply chain link: variables prone to fluctuations

The supply chain is the "lifeline" of OEM production of health products. Any problems in the procurement, transportation, and quality inspection of raw materials and packaging materials will directly affect the cycle, which is also a common cycle fluctuation factor in the industry, accounting for more than 40%.

In terms of raw material procurement, the procurement cycle for conventional raw materials (such as vitamins and minerals) is relatively short, only 7-15 days; Imported raw materials need to go through multiple processes such as customs clearance, international transportation, and domestic quality inspection, with a cycle of 30-45 days. Some imported raw materials also need to meet the registration requirements of General Administration of Customs Order 280. If the qualification review is not smooth, it will further delay. At the same time, some natural raw materials are greatly affected by the season, and it is necessary to lock up the goods three months in advance during the peak season, otherwise there may be supply interruptions or procurement delays.

The preparation of packaging materials is equally crucial. The procurement cycle for standard packaging materials (such as regular bottles and aluminum foil bags) is 10-14 days; If customized design, printing, and sample confirmation are required, the lead time will be extended to 20-30 days. It is worth noting that the new regulations have significantly increased the compliance requirements for packaging labels. If the label design does not comply with the "General Rules for Pre packaged Food Labeling in China", or if the overseas factory registration number (cross-border product) and blue hat filing information are omitted, it will result in packaging rework, reprinting, and an additional delay of 7-15 days.

（3） Production side control: dual impact of production capacity and quality

The production capacity scheduling, equipment status, and personnel configuration on the production end directly determine the efficiency of the mass production stage and are also one of the important reasons for delivery delays.

In terms of production capacity and scheduling, the spring and autumn seasons are the peak season for OEM of health products, with orders from top OEM companies saturated. New orders need to be queued for 7-15 days; If a customer urgently inserts an order, the original order will be passively postponed, further extending the cycle. Although small and medium-sized contract manufacturing enterprises have less queuing pressure, their production capacity is limited, and the production cycle for large orders will be longer than that of top enterprises.

Equipment and personnel configuration can also affect production efficiency. If the production equipment malfunctions and requires regular maintenance, it will result in unplanned downtime of 1-5 days; When multiple products are produced in parallel, changing lines for cleaning and process validation will also consume additional time. In addition, the lack of proficiency among frontline operators may result in quality abnormalities during the production process, leading to rework and prolonging the production cycle.

The order size also affects the cycle: although small batch orders (such as a minimum order of 500 units) have lower total production capacity requirements, they have higher unit time costs and lower production priority, resulting in longer cycles than medium batch orders; The production process for large orders is stable, but the total production time will increase accordingly, requiring advance planning and scheduling.

（4） Compliance and testing: the core reason for the extended cycle under the new regulations

In 2026, new industry regulations will be implemented intensively, and compliance and testing will become the focusOEM Health ProductsThe 'hard threshold' of production directly determines the upper limit of the production cycle, especially for blue hat products and cross-border products.

Ordinary food health products (SC qualification) only require factory self inspection (microbiological, heavy metal, active ingredient content, etc.), with a cycle of 3-7 days; And health food (blue hat) requires pre registration/filing, with a cycle of 6-12 months, and requires additional efficacy verification and stability testing, which takes 45-90 days. The new regulations further emphasize that the commissioning party must be the holder of the blue hat registration/filing certificate. If the brand owner fails to complete the filing in advance, it will not be able to start production, which will directly lead to a significant delay in the cycle.

For cross-border health product OEMs, General Administration of Customs Order 280 requires that overseas OEM factories must complete registration with the General Administration of Customs in China, and product labels must indicate the factory registration number, otherwise they cannot clear customs. In addition, if you need to apply for international certifications such as FDA, EU, organic, gluten free, etc., the testing and review process will be extended by an additional 20-30 days, further prolonging the overall cycle. At the same time, during peak season, third-party testing agencies face severe queues, resulting in delays of 5-10 days in the issuance of testing reports, which is also a common compliance delay factor.

（5） Customer factors: easily overlooked latency risks

The cooperation of the brand directly affects the efficiency of promoting OEM production of health products.

Delay in sample confirmation is a common problem. The normal sample confirmation cycle is 7 days. If the brand's decision-making process is cumbersome and sample requirements are repeatedly modified, the confirmation cycle will be extended to more than 15 days, directly causing delays in subsequent production processes. In addition, frequent changes in requirements during the production process (such as formula adjustments, specification modifications, label changes), especially pre production order changes, can lead to packaging material scrap and process re debugging, with a delay period of up to 10-15 days.

Meanwhile, delays in payment and submission of materials by the brand will also affect the progress of production. If the advance payment is not made as agreed in the contract, the factory will suspend material preparation and production scheduling; If the submitted qualification documents (such as trademark registration certificate, business license) are incomplete, it will hinder compliance review and delay production.

（6） External environment: Uncontrollable sudden risks

Although external force majeure factors are not common, once they occur, they have a significant impact on the production cycle, with such delays accounting for about 10%. In terms of logistics, the transportation of raw materials and packaging materials will be blocked and delayed for 3 – 7 days in holidays, special weather (rainstorm, typhoon) and traffic restrictions; In terms of policies, temporary spot checks by drug regulatory authorities and updates to industry regulations may lead to production suspension or process adjustments. Some products that fail the spot checks need to be reworked and re produced, with a delay period of up to 1-2 months.

In addition, unexpected situations such as the resurgence of the epidemic and environmental restrictions on production can lead to limited production capacity of OEM factories, and some factories in certain areas may even temporarily shut down, directly causing significant delays in order delivery.

2、 High frequency reasons for OEM delivery delays in health products (sorted by frequency of occurrence)

Based on industry research data, there is a clear concentration of reasons for OEM delivery delays in health products. Among them, supply chain delays, production scheduling issues, and compliance risks are the three core causes, accounting for over 80%, as follows:

（1） Supply chain delay (about 40%)

As a common cause of delay, supply chain delays are mainly concentrated in three aspects: firstly, delays in raw materials, including customs clearance obstacles for imported raw materials, supplier stockouts, transportation delays, especially for cross-border raw materials, where the probability of delay is higher; The second issue is packaging delay, which can be caused by repeated modifications to packaging design by the brand, printing errors, insufficient production capacity of packaging suppliers, or rework due to non compliant packaging labels; Thirdly, if the incoming materials are found to be unqualified, and heavy metals or microorganisms are found to exceed the standard during the testing of raw materials or packaging materials, they need to be returned or replaced, or re purchased, which usually results in a delay of 7-15 days.

（2） Production and scheduling issues (approximately 25%)

The problems on the production side mainly include capacity bottlenecks, equipment failures, and quality abnormalities. During peak season when orders are saturated, factory production capacity is insufficient, resulting in delays due to queuing of orders; Failure of critical production equipment with long maintenance cycles can result in unplanned downtime; Quality abnormalities that occur during the production process (such as non compliant active ingredients, non-conforming product form) require rework, scrapping, or re production, which can significantly extend the delivery cycle. Some serious abnormalities may even cause order delays of more than one month.

（3） Compliance and filing risks (approximately 15%)

After the implementation of the new regulations, compliance risks have become an important cause of delivery delays. The incomplete filing information of the blue hat and its rejection by the drug regulatory department may result in production being unable to start and delaying for 1-3 months; Non compliant product labels (such as missing registration information or overseas factory registration numbers) require redesign, printing, and reporting, with a delay of 7-15 days; Third party inspection queuing and failure to pass the inspection may result in the inability of the product to leave the factory, further delaying delivery.

（4） Customer communication and changes (approximately 10%)

The poor communication between the brand and the OEM factory, as well as frequent changes in demand, are human factors causing delays. Sample confirmation exceeding the deadline, modification of formulas, specifications, and quantities during production may cause interruptions in the production process; Delayed submission of materials and payment can lead to the factory halting material preparation and production scheduling, resulting in delayed delivery. Some brand owners are not familiar with the new regulations and have not prepared compliance materials in advance, which may indirectly prolong the cycle.

（5） External force majeure (approximately 10%)

Force majeure factors such as natural disasters (earthquakes, floods), logistics paralysis, temporary policy shutdowns and production restrictions, and epidemic control can directly lead to production suspensions and transportation disruptions. Although such delays are unpredictable, they have a significant impact on delivery, and some orders may even experience months of delay.

3、 Industry response suggestion: Avoid delay risks and shorten production cycles

Faced with multiple influencing factors and delivery delay risks in the OEM production cycle of health products, and in accordance with the new industry regulations in 2026, brand owners and OEM factories can improve their cycle control capabilities and reduce the probability of delays from the following five aspects:

1. Preliminary planning: Clarify product formula, dosage form, and packaging material requirements, confirm samples in advance, and avoid repeated modifications; Blue hat products need to be registered 6-12 months in advance, and cross-border products need to verify the registration qualifications of overseas factories in advance to ensure compliance.

2. Supply chain control: Prepare regular raw materials in advance, lock up the supply of imported raw materials three months in advance, and choose suppliers with complete qualifications and stable supply; Priority should be given to using mature templates for packaging materials, and customized packaging materials should be designed in advance and undergo compliance audits simultaneously to avoid rework.

3. Production collaboration: Avoid the peak season of the industry, choose top OEM companies with multiple production lines and backup capacity, and sign clear production scheduling agreements; Communicate production plans in advance to avoid the impact of urgent orders on existing orders.

4. Compliance control: Strictly prepare filing materials and design product labels in accordance with the new regulations, coordinate with testing agencies in advance, and avoid delays in testing queues; Entrust both parties to clarify compliance responsibilities, establish compliance review mechanisms, and promptly avoid compliance risks.

5. Contract agreement: Clearly define the delivery cycle, delay responsibility, requirement change process, urgent channel, rights and obligations of both parties in the OEM contract, reduce communication problems, and promptly handle any delays according to the contract agreement.

4、 Conclusion

With the increasingly strict regulation of the health product industry and fierce market competition, production cycle control and delivery stability have become the choices of brand ownersOEM manufacturingThe core considerations of partners are also a reflection of the core competitiveness of contract manufacturing enterprises. For brand owners, early planning and strengthening compliance are key to avoiding delivery delays and seizing market opportunities; For contract manufacturing enterprises, optimizing the supply chain, improving production capacity, and strictly controlling compliance are necessary to achieve a win-win situation with the brand. In the future, with the continuous improvement of industry standardization, compliance and flexibility will become the core trend of OEM production cycle control for health products.